EP0956046A4 - Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung - Google Patents

Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung

Info

Publication number
EP0956046A4
EP0956046A4 EP97940524A EP97940524A EP0956046A4 EP 0956046 A4 EP0956046 A4 EP 0956046A4 EP 97940524 A EP97940524 A EP 97940524A EP 97940524 A EP97940524 A EP 97940524A EP 0956046 A4 EP0956046 A4 EP 0956046A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapeutics
preparation
methods
cellular vaccines
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97940524A
Other languages
English (en)
French (fr)
Other versions
EP0956046A2 (de
Inventor
Yajun Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0956046A2 publication Critical patent/EP0956046A2/de
Publication of EP0956046A4 publication Critical patent/EP0956046A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97940524A 1996-06-12 1997-06-11 Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung Withdrawn EP0956046A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1963996P 1996-06-12 1996-06-12
US19639P 1996-06-12
PCT/US1997/010238 WO1997047271A2 (en) 1996-06-12 1997-06-11 Cellular vaccines and immunotherapeutics and methods for their preparation

Publications (2)

Publication Number Publication Date
EP0956046A2 EP0956046A2 (de) 1999-11-17
EP0956046A4 true EP0956046A4 (de) 2004-10-20

Family

ID=21794256

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97940524A Withdrawn EP0956046A4 (de) 1996-06-12 1997-06-11 Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung

Country Status (6)

Country Link
EP (1) EP0956046A4 (de)
JP (1) JP3676380B2 (de)
CN (1) CN1221349A (de)
AU (1) AU727955B2 (de)
CA (1) CA2258082A1 (de)
WO (1) WO1997047271A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
AU1013701A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
DE19957470A1 (de) 1999-11-24 2001-06-21 Actinodrug Pharmaceuticals Gmb Tetrahydropyrimidin-Dioxygenase-Gen sowie Verfahren zur enzymatischen in vivo und in vitro Produktion von hydroxylierten Tetrahydropyrimidinen
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
US7097841B2 (en) * 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP1531850B1 (de) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Verwendung von IL-21 und monoklonalem Antikörper zur Behandlung von fester Tumore
CA2678353A1 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
AU2009253539B2 (en) 2008-04-17 2014-03-20 Io Biotech Aps Indoleamine 2, 3-dioxygenase based immunotherapy
CN105925544A (zh) * 2016-06-27 2016-09-07 武汉思安医疗技术有限公司 一种包含4-1bb的慢病毒制备方法及应用
JP2020523018A (ja) * 2017-06-09 2020-08-06 プロビデンス ヘルス アンド サービシーズ−オレゴン がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610046A2 (de) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844893A (en) * 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610046A2 (de) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MACLEAN JAMES A ET AL: "Anti-CD3: Anti-IL-2 receptor bispecific monoclonal antibody: Targeting of activated T cells in vitro", JOURNAL OF IMMUNOLOGY, vol. 150, no. 4, 1993, pages 1619 - 1628, XP002156055, ISSN: 0022-1767 *
SAHIN U ET AL: "Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. JAN 1996, vol. 42, no. 1, January 1996 (1996-01-01), pages 9 - 14, XP002293245, ISSN: 0340-7004 *

Also Published As

Publication number Publication date
AU4228397A (en) 1998-01-07
CA2258082A1 (en) 1997-12-18
CN1221349A (zh) 1999-06-30
EP0956046A2 (de) 1999-11-17
AU727955B2 (en) 2001-01-04
JP3676380B2 (ja) 2005-07-27
WO1997047271A3 (en) 1998-02-12
JPH11514666A (ja) 1999-12-14
WO1997047271A2 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
EP0958364A4 (de) Immuntherapie und verbesserte impfstoffe
GB9620795D0 (en) Vaccines
AP9901444A0 (en) Erythrommycins and process for their preparation
AU4518196A (en) Adjuvant-incorporated cellular antigens: conjugation and methods
IL120124A0 (en) Heteroaryl-oxazolidinones their preparation and use
AU4648697A (en) Methods and devices for preparing protein concentrates
EP0958373A4 (de) Impfstoffe.
IL125622A0 (en) Novel erythromycin derivatives method for preparing same and use thereof as drugs
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
GB9806666D0 (en) Antigen preparation and use
EP0956046A4 (de) Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung
EP0872228A4 (de) Kosmetologisches verfahren
GB9816761D0 (en) Herpesvirus preparations and their uses
SG68625A1 (en) Quarternary bisphenolates methods for their preparation and uses thereof
HK1051544A1 (en) Novel hev antigenic peptide and methods
ZA9711565B (en) Vaccine
GB9920271D0 (en) Flavouring agent and methods for preparing and using same
EP0959795A4 (de) Filme mit verbesserten eigenschaften und ein verfahren zu deren herstellung undgebrauch
GB2331521B (en) Vaccine preparations
CZ20011896A3 (cs) Imunogenní prostředek a protilátka
AP9901454A0 (en) Novel erythromycin derivatives method for preparing same and use thereof as drugs
GB9920270D0 (en) Flavouring agent and methods for preparing and using same
GB9625968D0 (en) Vaccine
GB9609252D0 (en) Vaccines
ZA974108B (en) Antipicornaviral compounds and methods for their use and preparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990111

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990111;LT PAYMENT 19990111;LV PAYMENT 19990111;RO PAYMENT 19990111;SI PAYMENT 19990111

A4 Supplementary search report drawn up and despatched

Effective date: 20040906

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060503